Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT06563817

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

Led by Beijing Tiantan Hospital · Updated on 2024-08-21

53

Participants Needed

1

Research Sites

47 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This prospective, multicenter, open-label clinical trial is designed to evaluate the safety and efficacy of rapamycin in the treatment of communicating hydrocephalus secondary to intraventricular hemorrhage. Additionally, the underlying pathogenic mechanisms associated with this particular type of hydrocephalus will be investigated in greater depth, and populations that may benefit from rapamycin therapy will be identified.

CONDITIONS

Official Title

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with ventricular enlargement from intraventricular hemorrhage showing new gait disturbances, cognitive problems, or urinary incontinence after symptom remission, and brain imaging with Evans index 60.3
  • Age between 18 and 70 years
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Participation in another medical trial
  • Other diseases affecting symptoms like walking, cognition, or urinary control
  • Allergy to rapamycin
  • Reduced liver function with elevated INR or alanine transaminase over 1.5 times normal
  • Reduced kidney function with GFR less than 50
  • Taking strong CYP3A4/5 inducers or inhibitors such as diltiazem, ketoconazole, or rifampicin
  • Active or uncontrolled chronic infections
  • Pregnant or breastfeeding women
  • Bedridden patients or those needing long-term urinary catheters

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100070

Actively Recruiting

Loading map...

Research Team

R

Runfa Tian, MD

CONTACT

G

Guoyi Gao, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here